



# A cGMP Culture: What 503As Can Learn from 503Bs

**Amy Summers, PharmD, BCSCP**

Consultant

*Restore Health Consulting, LLC*

1

## Agenda

- The unique challenge of 503A compounding
- Implementation of advanced technologies
- Operational strategies to improve efficiency, safety, & compliance
- Quality culture
  - Regulatory strategy
  - Robust quality assurance program



2

# The Unique Challenge of 503A Compounding

It's hard to ensure reproducibility and reliability when  $N = 1$



3

## Manufacturing vs. Compounding

Manufacturing	Compounding
FDA approved drugs	Compounds
Large commercial scale batch sizes (>5000 units)	Small scale batches (1-250)
Use of automated filling machines	Manual processing
Reduced need for operator intervention or manipulation	Extensive human manipulation - interventions made from start to finish
Increased separation of operator from critical site	Operator in close contact with the critical site



4

## The Challenge is Personalized

- Compounds are patient-specific
- Small scale not commercial scale
- Several types of compounds are requested
- Several types of container/closures are used
- Machines do not match manual processing flexibility or cost to entry
- Manual methods are considered the riskiest of all aseptic processes



5

## FDA Warning Letter

Your firm **failed to sanitize tubing between production of different sterile drug products**. The tubing connected to the stock solutions of (b)(4) in IV bags located in the ISO 5 Laminar Flow Hood was not sanitized between the production of different sterile drug products. The investigator observed the operator touching the tubing several times during drug product production. Not sanitizing the tubing between the production of different sterile drug products could contribute to cross contamination of drug products.



6

## FDA Warning Letter

- **Poor aseptic technique was used** by personnel engaged in aseptic processing. This includes blocking first air to containers during aseptic processing, moving quickly within the ISO 5 classified IV room and placing sterile gloved hands on gowning during aseptic processing.
- Materials and supplies were not adequately disinfected prior to entering the aseptic processing area.



7

## FDA Warning Letter

During the production of Phenylephrine Hydrochloride, the investigator observed your technician leaning into the ISO-5 hood with her elbows and forearms touching the working surface inside the ISO-5 area.



8

# Implement Advanced Technologies

To improve efficiency, safety, & compliance



9

## Advanced Technologies

- Single-use mixing systems
- Single-use transfer tubing & IV bags
- Sterilization capsule filters
- Single-use connectors
- Advanced closed systems
- Sterile bulk containers & closures
- Tools
- Tabletop filling
- Pharmaceutical isolators
- CVEs & downflow booths
- Flexible nonsterile filling equipment & 3D printing
- QMS software



10

## Single-Use Mixing



Image Credit: Meissner Filtration Products



11

## Single-Use Tubing, Bags, & Sterilization Filters



Image Credit: MilliporeSigma




Image Courtesy of PALL Corporation



12

## Single-Use Connectors



Filling Bag



Dispensing Tubing  
Run Through a Pump

Needle or  
Connector



Image Credits: PALL Corporation, Meissner Filtration Products,  
Qosina Corp, Thomas Scientific, & Baxter



13

## Advanced Closed Systems




Image Courtesy of MDI Membrane Technologies



14

## Advanced Closed Systems



15

## Sterile Bulk Containers



Image Courtesy of Prince Sterilization Services



16

## Sterile Bulk Containers



*Image Courtesy of Prince Sterilization Services*



17

## Single-Use Tools



*Image Credit: Steris Life Sciences*



18

## Closed Container/Closure



Image Credits: Aseptitech

## Vial/Syringe Tabletop Filling




Image Courtesy of AST-Inc.

## Bag Tabletop Filling



Image Courtesy of Filamatic



21

## Pharmaceutical Isolator



Image Courtesy of Ecolab



22

## Powder Containment



Image Courtesy of Howorth



23

## Downflow Booth



Image Courtesy of Howorth



24

## Tabletop Filling



Image Courtesy of ATG Pharma



25

## 3D Printing




Image Courtesy of Fabrx



26

## QMS Software

- Dot Compliance
- Pestle
- Qualio
- Veeva
- Many more (some free)



27

## Operational Strategies

To improve efficiency, safety, & compliance



28

## Who am I and Why am I Here?

- Know your capabilities: What can you make?
- Know your capacities: How much can you make?
- Operate in a purpose-built facility
- Operate with equipment that's fit for purpose
- Use materials with appropriate quality attributes
- Stay within the confines of the 503A regulatory framework



29


## Key Elements to Success

- Detail the complete sterile compounding process design
- Minimize direct human interventions when possible
- Minimize interaction of operator with the environment
- Use advanced single use supplies that maintain a closed system
- Consider the type of PEC used
- Operators must exhibit good aseptic technique



30

## Provide Robust Training



31

## Have a Quality Unit



32




# Quality Culture

A cGMP culture is a quality culture

Alliance for Pharmacy Compounding  
Compounding the Joy of Living

Owner Summit

33



## Quality Culture as a Regulatory Strategy

- Why do you do what you do?
  - Patient safety
  - Less complaints, ADE, recalls & regulatory issues
  - Increased efficiency & revenue
- How do you get buy in?
  - Leadership
  - Training
  - Do what you say you do
  - Stay current
  - Give rewards

Alliance for Pharmacy Compounding  
Compounding the Joy of Living

Owner Summit

34

## Cost of Quality



People



Technology



Time

Quality is not a revenue generating department  
but it provides protection to the patient and therefore to the business.

35

## What does that look like?



People

Head of quality, personnel, auditor feedback



Tech

Track and report training, document control,  
equipment/facility maintenance/calibration,  
investigations/CAPA, incidents, etc.



Time

Training, spent away from operations

36

## Expected From Day 1

- Quality is non-negotiable
- Start with new employees - job description
- Built into the org chart, vision, values, meetings, SOPs
- Everywhere



37

## Challenges

- Lack of leadership involvement
- Lack of accountability
- Time to implement or improve changes
- Create systems and assurances



38

## References

- 21 CFR 211: Current good manufacturing practice for finished pharmaceuticals.
- United States Pharmacopeia Chapter <797>: "Pharmaceutical Compounding - Sterile Preparations", 2023 Version.
- Compounding: Inspections, Recalls, and other Actions.  
[www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions](http://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions).
- Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act  
Guidance for Industry.



39

## Contact Information

**Amy Summers, PharmD, BCSCP**  
**info@restorehealthconsulting.com**  
**(949) 329-2665**



40